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Abstract 
Historically, the FDA has interpreted the requirement that a drug must be “safe” to mean that the benefits of a drug outweigh its risks. 
The determination was made on a “categorical” basis, where the totality of risks was weighted against the totality of benefits when 
considered for the purposes outlined in the drug product’s labeling. If a drug did not meet this criterion, it was not approved or its label 
was rewritten to narrow the conditions for use. This logic was endemic in the FDA for most of the 20th century. On average, two to 
four drugs over each 5-year period were withdrawn from the marketplace after post-marketing surveillance data uncovered new risks. 
Similarly, on occasion, the FDA would require some special “tool” or intervention to improve a product’s safety profile. Harm associated 
with medication remains the second most common type of incident in hospitals, as reported by the Clinical Excellence Commission. 
Health services actively review medication safety. The vast majority of medication errors result in no injury.  A minor injury may result, 
for example, in a patient needing an increased level of monitoring.  Even if incidents result in minor injury, managers and staff still take 
any errors very seriously, reviewing the actions around the incident and making improvements as a result. FDA’s new concepts for risk 
management amount to a “cultural shift” in the logic of drug approval and the FDA’s role. The key events that led to this change can 
be traced to a series of reports that highlighted the need for improved medical safety. In 1999, the IOM released a report entitled, “To 
Err is Human.” This report reviewed the nature and cause of medication errors, estimating that up to 98,000 people died each year due 
to these errors. In their assessment, the IOM included both adverse drug reactions and human errors in drug administration. The report 
captured the attention of news reporters and the government. Headlines proclaimed alarm at the larger number of fatalities caused 
by medical errors. Consequently, there was a government-wide initiative started to develop methods and institute procedures to reduce 
medical errors. Statements made by FDA officials regarding some of these withdrawals suggested that the FDA no longer believed that 
passive oversight and re-labeling drugs with new warnings was sufficient. Furthermore, the FDA no longer believed that it was sufficient 
to identify safe conditions of use in the label and that healthcare professionals and patients had to comply with advocated directions 
of use for the drug to remain on the market. 
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1. Introduction 
There is also a misconception among some that the risk of, say, 
an adverse drug reaction in an individual is the same as its 
frequency in the population. However, it is possible for an 
individual, because of some susceptibility, to have a high risk of 
an adverse reaction that has a low frequency in the population. 
It is therefore best to separate notions of individual risk and 
population risk or frequency. As a summary of this new 
philosophy of risk management, the FDA staff issued a report to 
the Commissioner that highlighted processes for developing 
risk management systems and signaled new ideas for 
measuring and intervening to manage risks. US FDA (1999) 
Entitled, “Managing the Risks of Medical Products,” the FDA 
report borrowed heavily from risk management philosophies in 
other fields, such as environmental risk management and 
airline safety. It emphasized the process of developing risk 
management plans to control and manage drug safety. The risk 
management  
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 “revolution” at the FDA continues today. Under FDA 
regulations and the Food and Drug Administration’s 
Modernization Act, the FDA may approve new drugs with new 
restrictions that are intended to assure safe use (Subpart H). 
These restrictions include limiting distribution to certain 
facilities or physicians with special training or experience or 
limiting distribution based on the condition of the performance 
of specified medical procedures. The regulations specify that 
the limitations must be commensurate with the specific safety 
concerns presented by the product. In addition, drugs continue 
to be approved with restrictions imposed by manufacturers 
seeking FDA approval. The risk management guidance 
contained several revisions that addressed concerns from 
industry. The draft guidance stated that for certain drugs that 
pose risk management concerns, there must be a Risk MAP that 
describes what risks are faces and how they will be handled. 
The plan must identify a series of “tools” or interventions used 
to control risk. These tools include a series of informational 
interventions (to health care providers, patients, or the public) 
and distribution controls that specific conditions or populations 
of patient or providers that limit the prescribing or dispensing 
of the medication. The tools must be pretested, and the plan 
must be evaluated periodically. 
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1.1.  Risk perception in drug therapy 
Understanding risk and how it is perceived is a crucial step 
toward creating programs and campaigns to raise awareness 
and make communities safe. In short, risk perception, or the 
ability to discern risk, is tied to risk tolerance, or an individual’s 
capacity to accept a certain amount of risk. Risk perceptions 
(including deliberative, affective, and experiential) are often 
targeted in health behavior change interventions, and recent 
meta-analytic evidence suggests that interventions that 
successfully engage and change risk perceptions produce 
subsequent increases in health behaviors. Health-related risk 
perceptions play an important role in motivating health 
behavior change. The late Bill Inman once wrote that 
‘perception of risk is based less on statistics than on fear’, and 
there is little evidence that knowing what the actual risks are 
affects how the general public perceives and responds to them. 
The factors that lead to mistaken perceptions about the risks of 
using particular medicines have not been thoroughly explored, 
although some are known. For example, in a random sample of 
500 consumers aged 18 years and over in Wisconsin, 14–54% 
thought that generic prescription drugs were riskier than 
brand-name products, depending on the medical condition 
being treated, although financial incentives would have 
mitigated this view. There is also evidence that the more 
information consumers receive about the safety (or otherwise) 
of a medicine through direct-to-consumer prescription drug 
advertising in the USA the riskier they are likely to think it is. 
Media reporting is also thought to be important [1-4]. 
 
Exhibit 1. Several key terms and concepts are used in risk assessment [5] 
 Hazard: A source of risk, such as a substance or action that can cause harm. 
 Exposure: Contact with a hazard in such a manner that effective transmission of the agent or harmful 
effects of the agent may occur. 
 Dose-response relationship: A relationship in which a change in amount, intensity, or duration of 
exposure is associated with a change in the risk of the outcome. 
 Risk: The combination of the likelihood (probability) and magnitude (severity) of an adverse event. 
 Uncertainty: An instance of limited knowledge, false assumption, or statistical variability that contributes 
to a statement of confidence in conclusions drawn from a risk assessment. 
 Risk management: The process of formulating and implementing a course of action to mitigate hazards 
determined by risk assessment to be important. 
 
1.2. The objective of therapeutic risk management 
Deployment of healthcare risk management has traditionally 
focused on the important role of patient safety and the 
reduction of medical errors that jeopardize an organization’s 
ability to achieve its mission and protect against financial 
liability. The hazards of not preparing for potential issues can 
have significant, long-term effects. Neglecting to have 
comprehensive risk management plans in place can 
compromise patient care, increase liability risks, and result in 
financial losses. Thus, potential risks have to be evaluated and 
measured in terms of their potential negative effects. Based on 
the risk assessment, an organization-specific management plan 
should be developed, implemented, and monitored. Given that 
each organization faces unique challenges, there is not a one-
model-fits-all risk management solution. For example, the CDC 
recently published research that found that prolonged urinary 
catheter use is the leading risk factor for catheter-associated 
urinary tract infections. Based on this information, a risk 
management plan was implemented requiring physicians to 
regularly evaluate the catheter. The end result was a decrease 
in patient risk. Challenges faced by administrators that should 
be addressed in a risk assessment plan include but are not 
limited to: 
• Patient safety 
• Mandatory federal regulations 
• Potential medical error 
• Existing and future policy 
• Legislation impacting the field of healthcare  
Risk Management can be Beneficial in the Following Contexts: 
• ERM: Comprehensive risk management of the 
organization from top down including financial and 
business viability. 
• Patient care (Clinical) 
• Medical staff (Such as; credentialing, privileging, job 
description, employee insurance, trainings, medical 
coverage) 
• Non-medical staff (Such as; job description, training, 
medical coverage) 
• Financial (Budgeting, cost-benefit and cost-effectiveness 
analysis, insurance coverage) 
• Managerial (Such as; organogram, Job descriptions, 
delegation of work) 
• Project risk management (Such as scope, time, cost, 
human resources, operational, procedural, technical, 
natural and political) 
• Facility Management and safety (Such as building safety, 
security of the facility, HAZMAT, emergencies internal and 
external, fire safety, medical equipment maintenance plan 
and maintenance plan for each of the utility system [6-
10]. 
 
1.3.  The Role of Healthcare Risk Managers: Risks to patients, 
staff, and organizations are prevalent in healthcare. Thus, 
it is necessary for an organization to have qualified 
healthcare risk managers to assess, develop, implement, 
and monitor risk management plans with the goal of 
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minimizing exposure. There are many priorities to a 
healthcare organization, such as finance, safety and most 
importantly, patient care. Healthcare managers identify 
and evaluate risks as a means to reduce injury to patients, 
staff members, and visitors within an organization. Risk 
managers work proactively and reactively to either prevent 
incident or to minimize the damages following an event. 
Risk managers are trained to handle various issues in 
multiple settings. The duties a risk manager undertakes are 
ultimately determined by the specific organization. These 
professionals typically work in the following areas of 
medical administration: 
• Financing, insurance, and claims management 
• Event and incident management 
• Clinical research 
• Psychological and human healthcare 
• Emergency preparedness 
 
A risk manager is often someone who has experience in 
handling risk-related issues in multiple settings. This 
individual should be able to identify and evaluate risks, 
which should then reduce the potential for injury to 
patients, staff members and visitors. For example, a 
registered nurse should notice if a bed rail should be 
modified. But detecting risks and making adjustments to 
reduce those risks goes much further. They include not 
filling expired prescriptions (prevents abuse), following up 
on missing test results (to increase consultations), tracking 
missed appointments (to manage risks), increased 
communication with patients (reduce improper taking of 
medication), and preventing falls and immobility. With the 
expanding role of healthcare technologies, increased 
cybersecurity concerns, the fast pace of medical science, 
and the industry’s ever-changing regulatory, legal, political, 
and reimbursement climate, healthcare risk management 
has become more complex over time. For these reasons, 
hospitals and other healthcare systems are expanding their 
risk management programs from ones that are primarily 
reactive and promote patient safety and prevent legal 
exposure, to ones that are increasingly proactive and view 
risk through the much broader lens of the entire healthcare 
ecosystem [7], [12,13]. 
 
2. Key Components of Performing Risk Management 
Risk management in health care is defined by clinical and 
administrative activities undertaken to identify, evaluate, and 
reduce the risk of injury to patients, staff, and visitors and the 
risk of loss to the organization itself. With the release of the risk 
management draft guidance the FDA has come to the 
conclusion that it is necessary to fully consider the risk 
management process for certain products considered for 
approval and for continuous marketing. 
 
  
2.1. Identify Risk: Since risk management involves managing 
uncertainty and new risk is constantly emerging, it is 
challenging to recognize all the threats a healthcare entity 
faces. However, through the use of data, institutional and 
industry knowledge, and by engaging everyone — patients, 
employees, administrators, and payers—healthcare risk 
managers can uncover threats and potentially 
compensatory events that otherwise would be hard to 
anticipate. Sources of risk identification: 
 
Discussions with department Chiefs, managers and staff Patient 
Tracer Activity (Tracing the journey of a patient from admission 
until discharge): 
• Retrospective screening of patient records 
• Reports of accreditation bodies 
• Incident reporting system & Sentinel events 
• Healthcare Associated Infections (HAI) reports 
• Executive committee reports 
• Facility management & safety committee report 
• Patient complaints and satisfaction survey results 
• Specialized committee reports (such as Morbidity and 
mortality committee, medication management and use, 
infection control, blood utilization, facility management 
and safety committee) [6], [10] 
 
2.2. Risk Assessment:  For most medicines the benefits are 
limited to a few indications and for an individual patient 
there is usually only a single benefit sought but the 
potential risks are multiple. Although at the time of 
approval knowledge about efficacy from small, short-term 
clinical-trial populations is limited, far less is known about 
the drug’s risks. The evaluation of the benefit: risk ratio of 
a drug is essential throughout the whole life cycle of a drug. 
During the discovery phase, the analysis of the biological 
targets as well as medical chemistry will allow selection of 
lead molecules with the best BRA potential over hundreds 
of candidate molecules. The review of the benefits and the 
risks associated with a drug is called benefit: risk 
assessment (BRA), or benefit-risk balance, or benefit-risk 
ratio evaluation. BRA is basically an evaluation of two 
dimensions. The dimension of benefits is measured 
primarily in terms of therapeutic efficacy, i.e., the 
successful treatment of the condition for which the drug is 
indicated. There are other types of benefits, such as 
improvement of quality of life or pharmacoeconomic 
aspects, that are of interest in a period where the costs of 
medicine are closely scrutinized. The dimension of risks 
includes the safety profile observed in the form of the sum 
of all ADRs, but also includes the potential risk of 
unobserved ADRs anticipated on the basis of the 
mechanism of action [13-15]. 
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2.3. Risk Quantification: In Europe, part of the mandate of the 
CHMP is to assess risks and benefits of authorized 
medicines on behalf of the EMEA. In 2007, the CHMP 
revised its guidance and included quantitative BRA in the 
regulatory agenda with the publication of a report 
examining the potential value of existing benefit–risk 
models and methods. Although no specific method was 
recommended, several BRA features were noted as being 
of value, including 1) all important benefits and medically 
serious risks are identified; and 2) the risks and benefits are 
weighted according to their relative importance and the 
strength of the evidence available. It was also decided that 
a comprehensive review of available quantitative methods 
for BRA relevant to the CHMP was required to explore 
further development of tailored methodologies. The EMEA 
created the ENCePP, which is in the process of developing 
an algorithm to articulate safety and benefit profiles for 
pharmaceutical products [16-18]. 
 
2.4. Development and Implementation of Risk Management 
Tools (eg, Risk Communication and Distribution and 
Behavioral Control Systems): Unsafe health care provision 
is a main cause of increased mortality rate amongst 
hospitalized patients all over the world. A system approach 
to medical error and its reduction is crucial that is defined 
by clinical and administrative activities undertaken to 
identify, evaluate, and reduce the risk of injury. WHO draft 
guideline and patient safety reports from different 
countries were reviewed for defining acceptable 
framework of risk management system. 7 steps in the Risk 
Management process are establishment the context, 
identifying, analyzing, evaluating, and treating the risks, 
continuous monitoring and review, and communication 
and consultation. The literature reports on many different 
methods, strategies, and measures to introduce 
innovations, guidelines, best practices, or new procedures 
into clinical practice. Effective implementation of 
innovations seems to be more successful with strategies 
for implementation that are tailored to the specific goals, 
target group and setting [19,20]. 
 
2.5. Evaluation of the Effectiveness of tools and 
implementation of design modifications: The design and 
conduct of a range of experimental and non-experimental 
quantitative designs are considered. Such study designs 
should usually be used in a context where they build on 
appropriate theoretical, qualitative and modelling work, 
particularly in the development of appropriate 
interventions. Evaluation informs the choice between 
alternative interventions or policies by identifying, 
estimating and, if possible, valuing the advantages and 
disadvantages of each. Campbell and colleagues have 
suggested that the evaluation of complex interventions 
should follow a sequential approach involving: 
 
 
 Development of the theoretical basis for an intervention; 
 Definition of components of the intervention (using 
modelling, simulation techniques or qualitative methods); 
 Exploratory studies to develop further the intervention 
and plan a definitive evaluative study (using a variety of 
methods); 
 Definitive evaluative study (using quantitative evaluative 
methods, predominantly randomized designs) [21]. 
 
3. Overview of risk management around the world 
 ENCePP: In 10 years, the ENCePP has made a major 
contribution to the benefit-risk evaluation of medicinal 
products in Europe and beyond by providing 
methodological recommendations complementing 
regulatory guidance on PASS. Perhaps most importantly, 
ENCePP has created a strong European community 
supporting methodological standards, transparency, and 
scientific independence in pharmaco-epidemiological 
research [22]. 
 ASHRM: ASHRM Annual Conference and Exhibition 2019 
is going to take place in Oct 13 - 16, 2019 (Baltimore, 
Maryland) with the mission statement “To provide health 
care risk managers with the resources, knowledge and 
support to strategically and broadly manage risk, reduce 
uncertainty, add value, and advance health and safety”. 
The identified risks were confirmed through a survey of 
risk managers from a range of global healthcare 
organizations during the ASHRM conference in 2017. In 
2014, the ASHRM proposed risk domains for healthcare 
organizations, but again, risk events and scenarios are not 
described in detail. Other institutions, such as HIROC 
(Canada) and the NHS (England) have developed risk 
taxonomies that include clinical risks and enterprise risks. 
Finally, the risks are categorized by group using the 
ASHRM domains and COSO factors as guidelines [23-25]. 
 HIROC: HIROC, together with IRM Steering Committee 
comprised of risk management experts from various 
healthcare organizations, developed a web-based IRM 
Risk Register program in 2014. The 2016 top active risk 
themes were: patient care (30%); human resources (16%); 
financial (12%); leadership (11%); and information 
management/technology (10%). The top five active        
risks (by frequency) were: revenue/funding, 
regulatory/legislation; care communication; medication; 
and recruitment/retention of staff. The top five active 
risks (by rating) were: access to care, accreditation, 
adverse events, aging/maintenance of infrastructure, 
benefits/overtime [26]. 
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Exhibit 2. 7 steps to IRM detailed by Borovoy, 2019 [27] 
 Exploration & Decision  
 Risk Register Sign-On 
 Ownership & Coordination 
 Risk Identification 
 Risk Register Validation 
 Sustainability & Review Process 
 Risk Register IRM Ongoing Development & Knowledge Sharing 
 
4. Healthcare Risk Management Plan 
Medicinal products are given authorization on the basis that, 
the   risk-benefit balance is judged to be positive for the target 
population   at the time of authorization. They appear to be safe 
and well tolerated  but safety in actual world is unclear as there 
are many limitations during clinical trials as medicinal products 
are studied in homogeneous  population in limited number in 
ideal conditions and with limitations  in  terms  of  age,  sex,  
race  and  ethnicity;  co-morbidity,  restricted  co- medication,  
relatively  short  duration  of  study  and  follow  up  and  the   
marketed  drug  addresses  huge  population  and  relatively  
longtime   exposure. Thus, risk management plan plays a vital 
role in both pre and post approval of drug The Risk 
Management Plan becomes the guiding document for how an 
organization strategically identifies, manages and mitigates 
risk. Hospital leadership and all department heads should be 
aware of and involved in the development and on-going 
evaluation of the plan. Healthcare risk management plans 
communicate the purpose, scope, and objectives of the 
organization’s risk management protocol. They also define the 
roles and responsibilities of the risk manager and other staff 
involved in risk mitigation. Reviewing other studies is one way 
to develop risk management programs. Following the directives 
of governing organizations such as the Department of Health 
and Human Services, FDA and ASHRM ensures risk 
management compliance.  Using analysis results, risk managers 
can compare the likelihood of different adverse events along 
with their impacts and rank potential risks in terms of severity. 
Plans for mitigating risks and handling them appropriately can 
then be developed. Risk management plans also undergo 
quality assessments so the interventions and actions proposed 
are addressed as real potential issues. Once a strategy is in 
place, it is monitored and modified as needed [6,7]. 
  
Exhibit 3. USAID detailed Risk Management Plan steps [28] 
 Step 1: Establish your context  
 Step 2: Identification of possible risks  
 Step 3: Assessment  
 Step 4: Potential risk treatments  
 Step 5: Create a risk management plan  
 Step 6: Implementation  
 Step 7:  Evaluate and review 
 
4.1. Effective Patient Care Practices 
The development and implementation of healthcare risk 
management programs are based on extensive ongoing 
research. Risk managers must stay up-to-date on relevant 
information in their organization because research results 
could prove contradictory to presumptions that would 
otherwise shape risk management practices. For example, one 
study published by JAMA Internal Medicine revealed that 
increasing the hours of sleep residents in teaching hospitals 
received actually compromised patient safety. The risk-
management outcome was to ensure that strategies were in 
place to improve resident’s sleep schedules and reduce 
potential risks to patients. There are several challenges ahead 
for cultivating an effective and positive safety culture in 
healthcare organizations. To keep pace with international 
standards, healthcare managers must employ modern methods 
of management in order to overcome the challenges faced by 
the institutionalization of safety culture and to make a 
difference in the healthcare system. Safety experts have 
suggested the essential components for safety culture such as 
teamwork, leadership support, communication, and a just 
culture as well as a reporting and a learning culture [6], [29]. 
 
4.2.  RMP safety specifications 
It summarizes on important identified risks, important potential 
risks, and missing information due to limitations of clinical 
trials. It helps to identify needs for data collection and helps in 
the construction of pharmacovigilance plan. The purpose of the 
safety specification in the RMP is to provide a synopsis of the 
safety profile of the medicinal product(s) in the intended 
population as described in the approved Summary of Products 
Characteristics (e.g. therapeutic indications, or 
contraindications), and should include what is known and areas 
of uncertainty about the medicinal product(s). In the safety 
specification of RMP, important identified or potential risks or 
missing information related to the use of the medicinal 
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products in the target population and potential off-label use, 
should be discussed with reference to pharmacogenomics. The 
aspects indicated below should be considered [30]. 
 
4.3.  Implementing Strategies for Patient Care 
In clinical studies, for example, IRBs monitor proposed research 
plans before they are implemented to ensure minimal risk to 
human subjects. Plans for risk management must cover patient-
specific risks and be well documented; they must also be 
accessible to those working with patients. Research indicates 
that clinical guidelines are often not applied. The success of 
their implementation depends on the consideration of a variety 
of barriers and the use of adequate strategies to overcome 
them. It is estimated that about 30%–40% of patients receive 
treatment that is not based on scientific evidence, and 20%–
25% receive treatments that are either not needed or 
potentially harmful. In addition, it is estimated that more than 
50% of Americans do not take medications as they are 
prescribed, and approximately one third do not finish the 
course of therapy or skip doses. A successful introduction of 
guidelines involves the three steps of development, 
dissemination and implementation. Many patient risks can be 
reduced by adequately training physicians and staff, 
encouraging strong communication among staff-members, 
providing counseling services for those working with patients, 
and conducting competency assessments. Other risks posed to 
patient safety can be mitigated using patient-specific risk 
management strategies such as: 
 
 Not filling expired prescriptions: Interpersonal 
communication is inherent in a majority of strategies 
seeking to engage health care professionals in the 
reduction and prevention of prescription drug abuse. 
Sending patients adequate notification of prescription 
expiration will support communication between patients 
and physicians thus reducing potential prescription 
medication abuse. 
 Following up on missing test results: Failure to follow-up 
can lead to missed or delayed diagnoses which impact on 
patient care and can also have medico-legal implications 
for health services and health professionals. Patients who 
need to take additional medical tests following 
appointments may fail to do so, or the test results might 
get lost. Developing a plan to monitor receipt of test results 
guarantees the results are reviewed, so patients can then 
be consulted. 
 Tracking missed appointments: The problem with missed 
appointments is that continuity and effectiveness of 
healthcare delivery is compromised, appropriate 
monitoring of health status lapses, and he cost of health 
services might increase. Furthermore, some studies have 
shown a relationship between missed appointments and 
sub-optimal clinical outcomes among patients with chronic 
diseases Implementing a system to follow-up with patients 
who miss appointments but fail to reschedule is another 
proactive step in managing patient risks. 
 Communicating with patients: Evidence supports the 
importance of communication skills as a dimension of 
physician competence. Effort to enhance teaching of 
communication skills to medical trainees likely will 
require significant changes in instruction at 
undergraduate and graduate levels, as well as changes 
in assessing the developing communication skills of 
physicians. Patients may have limited understanding 
of information received from physicians. Having a 
strategy that checks the patient’s comprehension of 
information reduces the likelihood that the patient will 
misinterpret a physician’s orders or will improperly 
take medication. Successful communication should be 
uncomplicated, be specific, use some repetition, 
minimize jargon, check patient understanding. 
 Prevent falls and immobility: Although estimates of 
fall rates vary widely based on the location, age, and 
living arrangements of the elderly population, it is 
estimated that each year approximately 30% of 
community-dwelling individuals aged 65 and older, 
and 50% of those aged 85 and older will fall. Of those 
individuals who fall, 12% to 42% will have a fall-related 
injury. Making minor modifications to things like bed 
rails, bathtubs and toilets lacking grab bars, 
institutional lighting, and the conditions of the ground 
can significantly reduce the risks of such hazards. 
 Sufficient record retention - Keeping patient records 
on file for an extended period of time or indefinitely is 
useful for monitoring patient health, even when 
patients are not actively seeking care. Risk 
management protocol should also have plans in place 
for disposing of records in accordance with federal 
mandates. However, the widespread use of EHRs was 
delayed by high costs, data entry errors, poor initial 
physicians’ acceptance, and lack of any real incentive. 
The goal of replacing the entire paper chart with an 
electronic record was considered problematic due to 
the large initial costs resulting in the view that only key 
data should be computerized. As a result, the EHR 
would complement and not replace the paper record 
[31-37]. 
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Exhibit 4. EU pharmacovigilance terminology [38] 
Term EMA definition 
Abuse  Persistent or sporadic, intentional excessive use of medicinal products which is accompanied by harmful physical or psychological effects [DIR 2001/83/EC Art 1(16)] 
Medication 
error 
An unintended failure in the drug treatment process that leads to, or has the potential to lead to, 
harm to the patient 
Misuse  Situations where a medicinal product is intentionally and inappropriately used not in accordance with the terms of the marketing authorization 
Occupational 
exposure  
For the purpose of reporting cases of suspected adverse reactions, an exposure to a medicinal 
product as a result of one’s professional or non-professional occupation. It does not include the 
exposure to one of the ingredients during the manufacturing process before the release as 
finished product 
Off-label use 
Situations where a medicinal product is intentionally used for a medical purpose not in 
accordance with the terms of the marketing authorization. Examples include the intentional use 
of a product in situations other than the ones described in the authorized product information, 
such as a different indication in terms of medical condition, a different group of patients (e.g. a 
different age group), a different route or method of administration or a different posology. The 
reference terms for off-label use are the terms of marketing authorization in the country where 
the product is used 
Overdose 
Administration of a quantity of a medicinal product given per administration or cumulatively 
which is above the maximum recommended dose according to the authorized product 
information. When applying this definition, clinical judgement should always be applied 
 
5. Pharmacovigilance planning 
An RMP serves as the central document in pharmacovigilance 
activities for an individual product, and contains three 
elements: (1) a safety specification describing the potential and 
identified risks as well as important missing information on 
adverse effects, (2) the pharmacovigilance plan, which 
describes proposals to acquire more data on possible risks, 
identified risks, and missing information, and (3) the risk 
minimization plan. RMPs are prepared and maintained by the 
pharmaceutical companies, but require approval by regulatory 
authorities, who may require companies to add new risks to the 
RMP or to initiate new risk minimization activities, including 
new studies for safety or efficacy. The newest EU legislation 
requires a summary of the RMP to be made public. In 
November 2013, a team of European regulators initiated the 
SCOPE Joint Action; The SCOPE Joint Action was a public 
initiative co-ordinated by the MHRA in the UK. The SCOPE 
project evaluated then-current practices and developed tools 
to further improve the skills and capability in the 
pharmacovigilance network. The project was divided into eight 
separate work streams, five of which concentrated on 
pharmacovigilance topics—collecting information on suspected 
adverse drug reactions, identifying and managing safety issues 
(signals), communicating risk and assessing risk minimization 
measures, supported by effective quality management 
systems. The other three work streams focused on the 
functional aspects—coordination, communication and 
evaluation of the project. Through the project, SCOPE delivered 
guidance, training in key aspects of pharmacovigilance, and 
tools and templates to support best practice. 2015 marks an 
important milestone in the maturity of medical biotechnology, 
with five or more biosimilar applications pending review by the 
US FDA. For the first time, a number of manufacturers will 
produce a series of highly similar but not identical medicines for 
the US market. It is important that the specific biologic or 
manufacturer is readily identified to ensure accurate tracing of 
AEs to the administered product. Increased use of barcodes on 
biologic drugs should improve tracing capabilities, as should 
implementation of the US DQSA/DSCSA, which outlines use of 
an interoperable electronic system to identify and trace 
prescription drugs in the USA. In the USA, post-approval safety 
signal detection is performed primarily using SRS and AS 
systems. SRSs (e.g., MedWatch and institution-based reporting) 
are considered passive surveillance methods, which rely on 
voluntary reports from physicians, pharmacists, other 
healthcare providers, and patients. AS methods include 
retrospective analysis of medical records at Sentinel-affiliated 
sites and drug or disease registries, as well as use of drug event 
monitoring (e.g., surveys of patients identified through 
electronic prescription data. Brand name reporting for biologics 
in SRSs can vary by the product class and jurisdiction. For 
example, 84 % use of accurate brand names has been reported 
for insulins in the USA, whereas product-specific attribution of 
epoetins approached 99 % in the European Union (EU).In recent 
years, the scope and objectives of pharmacovigilance have 
expanded manifold due to changes in the global pharma 
environment, improved access to medicines, varied utilization 
of medicines and availability of newer, more powerful tools and 
databases for tracking and analyzing data; however, the 
discipline needs to evolve further to meet both public health 
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system needs and consumer expectations. The recent efforts 
directed to enable the shift toward proactive PV and 
establishing global PV practices show that harmonized PV 
practices are required to meet the needs of the various 
stakeholders in PV (including health authorities, the 
pharmaceutical industry, health-care professionals, and 
consumers). In addition, harmonization would also promote 
the safer use of medicines and public health protection. The 
existing working practices of a particular region are directly 
correlated to the PV legislation that exists in that region. By 
defining the minimal requirements and practices, PV legislation 
thereby helping define how safety information about medicinal 
products is reported to enable adequate benefit-risk 
assessment. While much progress has been made in PV 
practices, many deficiencies and issues still exist in the efforts 
to ensure safe medicine usage. It requires formal training for PV 
professionals and better communication tools. Safety 
information is communicated between different regulatory 
agencies, regulatory agencies and manufacturers, healthcare 
professionals and manufacturers, agencies and healthcare 
professionals, healthcare professionals and consumers. All 
parties in communication utilize different tools– from product 
labeling to adverse event reports [38-43].  
 
Drug Adverse event 
Sodium glucose co-transporter 2 inhibitors  Diabetic ketoacidosis (atypical presentation)  
Risperidone  Cerebrovascular events in patients with dementia  
Infliximab  Non-melanoma skin cancers (particular in psoriasis)  
Methotrexate  Hepatitis B reactivation  
Non-steroidal anti-inflammatory drugs (over-
the-counter doses used for prolonged periods)  
Cardiovascular events  
Diclofenac – hepatotoxicity  
Combined oral contraceptives and hormonal 
replacement therapy  
Potential link with inflammatory bowel disease  
Metoclopramide  Extrapyramidal events and cardiac conduction – new 
recommendations for prevention  
Pregabalin  Suicidal ideation  
Zolpidem  Next day impairment  
Duloxetine  Serotonin syndrome  
Rotavirus vaccine  Intussusception  
Denosumab  Severe hypocalcemia  
Proton pump inhibitors  Acute interstitial nephritis  
Clozapine  Constipation  
Exenatide  Pancreatitis  
 
6. Developing risk minimization plans/risk mitigation 
strategies 
An RMP documents the risk management system required to 
identify, characterize and minimize a product’s important risks. 
The TGA requires RMPs to be submitted for evaluation with 
certain higher-risk applications to enter a medicine or biological 
in the ARTG or to vary an ARTG entry. An RMP (or RMP update) 
will normally be expected with applications involving a 
significant change to an existing registration, such as a: 
significantly different population; pediatric indication; new 
dosage form or route of administration with inherently higher 
risk (e.g. oral tablets vs IV injection); new manufacturing 
process of a biotechnologically-derived product or other 
significant change in indication. RMPs must be maintained 
throughout the lifecycle of the product and important updates 
submitted to the TGA for evaluation. A new RMP has to be 
submitted whenever TGA requests; whenever there is a 
significant (material) change to the RMP, including but not 
limited to: when the RMP is modified as a result of new 
information that may lead to a change to the benefit-risk 
profile; when an important (product vigilance or risk 
minimization) milestone is reached; or an activity is terminated, 
added, or substantially altered; when changes to the summary 
of ongoing safety concerns are made. This guidance: 
 Explains when you must submit an RMP with an application 
for registration, inclusion or variation in the ARTG 
 Describes what to include in an RMP and the required 
format for RMPs 
 Details special requirements for RMPs for biologicals 
 Outlines how the TGA evaluates RMPs 
 Explains when to submit RMP updates after regulatory 
approval 
 Describes how the TGA monitors sponsor compliance with 
RMP commitments 
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Similarly, Companies are required submit an RMP to the EMA 
when applying for a marketing authorization. To help 
applicants, EMA developed guidance on how to submit RMPs. 
RMPs include information on: 
 A medicine's safety profile; 
 How its risks will be prevented or minimized in patients; 
 Plans for studies and other activities to gain more 
knowledge about the safety and efficacy of the medicine; 
 Measuring the effectiveness of risk-minimization 
measures. 
In the EU, companies must submit an RMP to the Agency at the 
time of application for a marketing authorization. For medicines 
that do not have an RMP, one may be required with any 
application involving a significant change to the marketing 
authorization. In addition, for nationally authorized medicinal 
products, any NCA in the EU can request an RMP whenever 
there is a concern about a risk affecting the benefit-risk balance 
of a medicine. RMPs are continually modified and updated 
throughout the lifetime of the medicine as new information 
becomes available. Companies need to submit an updated 
RMP: 
 At the request of EMA or an NCA; 
 Whenever the risk-management system is modified, 
especially as the result of new information being received 
that may lead to a significant change to the benefit-risk 
profile or as a result of an important pharmacovigilance or 
risk-minimization milestone being reached. 
When justified by risk, the competent authority can also specify 
a date for submission of the next RMP as a condition of the 
marketing authorization in exceptional cases. RMPs can only be 
submitted at the same time as the PSUR if the change in the 
RMP comes as a consequence of the PSUR [44,45]. 
 
7. Planning and implementation of Risk Minimization 
Measures (RMMs) 
An important element of risk management is the planning and 
implementation of RMMs and the evaluation of their 
effectiveness by process or outcome indicators. The 
effectiveness of RMMs can be evaluated by process and/or 
outcome indicators. Process indicators measure the extent to 
which a program was implemented, whether the execution was 
as planned, and the impact on knowledge and behavior of the 
target population. Outcome indicators provide an overall 
measure of the level of risk control achieved by RMM, for 
example, measuring rates of an adverse drug reaction or other 
safety-related outcome. Evaluation of effectiveness of RMMs is 
important to manage the benefit-risk balance of a medicinal 
product. Effectiveness of RMMs can be evaluated by using 
cross-sectional survey studies and studies using secondary data 
sources. The EU PAS Register proves to be a valuable resource 
for identifying studies evaluating the effectiveness of RMMs in 
Europe. Half of the effectiveness indicators (process and/or 
outcome) were reported as successful [45]. 
 
Exhibit 6. A suggested set of strategic activities by the risk minimization function [46] 
 Leading strategic planning for risk minimization activities for the research portfolio as a whole as well as 
for individual products; 
 Executing or overseeing the execution of “best-in-class” risk minimization program design, 
implementation, and evaluation using knowledge from implementation science in health; 
 Conducting targeted research to develop improved risk minimization tools, methodologies, and 
evaluation approaches that support the company’s pipeline and marketed products’ portfolio; 
 Establishing a knowledge management system that: a) documents both internal and external “lessons 
learned” and the evolving risk minimization requirements and practices of regulatory authorities 
worldwide, and b) promulgates best practices in risk minimization science to internal teams; 
 Optimizing operational and cost efficiencies of risk minimization processes by standardizing processes 
where appropriate and leveraging preferred supplier and service provider arrangements; 
 Publishing risk minimization evaluations and research findings in order to advance the science in a “pre-
competitive” context; and 
 Achieving a sustained level of compliance globally with regard to risk minimization commitments through 
standard setting, monitoring, and ongoing technical support to company affiliate offices. 
 
8. Incorporating Risk Management and Quality 
Improvement into Organizational Planning 
Quality improvement involves a combined effort among health 
care staff and stakeholders to diagnose and treat problems in 
the health care system. However, health care professionals 
often lack training in quality improvement methods, which 
makes it challenging to participate in improvement efforts. 
Quality improvement and the management of risks in health 
care should be part of both strategic and operational planning 
in every area and service of healthcare delivery, clinical and  
 
nonclinical. Risk management and quality improvement should 
be considered as an integrated approach when determining 
clinical practice, equipment design and procurement, capital 
development, information technology, contractor 
management, workplace health and safety, workforce 
management, and financial planning, and all other areas of 
operation.    
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Figure 1: Risk management process overview (Source: AS/NZS ISO 31000 — 2009 Risk management — principles and guidelines) 
 
Healthcare organizations’ systems for risk management and 
quality improvement are reviewed within the NSQHS Standards 
under Standard 1: Governance for Safety and Quality in Health 
Service Organizations. In addition, NSQHS Standards 3-10 
require organizations to undertake a risk assessment of their 
systems. For example, NSQHS Standard 4 requires a risk 
assessment of medication management systems. These risk 
assessments are managed by the associated governance 
committees with key risks also being represented on the 
organization-wide Risk Register. The same applies for quality 
plans. Organizations are required to submit a Quality 
Improvement Plan at each phase of their accreditation cycle 
and have a register of the organizational risks (Risk Register) 
available for ACHS surveyors at each onsite survey. For risk 
management and quality improvement programs to be most 
effective, the governing body and leadership team must 
demonstrate commitment to the processes and define their 
expectations for all stakeholders. In addition, the leadership 
team should ensure that there are sufficient resources to meet 
the requirements of the organization and systems to effectively 
mitigate, control and manage all risks, and that attention is 
focused on the core business of the organization – to care for 
and treat consumers / patients in a safe and high-quality clinical 
environment. Risk management and quality improvement 
systems are both directed to providing a structured framework 
for identification, analysis, treatment / corrective action, 
monitoring and review of risks, problems and/or opportunities. 
Communication and consultation with stakeholders are critical 
for these processes to work effectively.  Continuous 
improvement and risk management are data driven. They 
depend on relevant information being provided to the 
executive, clinicians, managers and the governing body. The 
data and information provided should reflect the issues that are 
most significant to the organization, rather than just for the 
process of data and information collection itself. A range of 
tools that can be used for quality improvement also applies to 
analyzing risk issues [47-51].  
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Exhibit 7. The integrated risk management and quality improvement  
framework, documented in a plan that is provided to all staff members [47] 
Risk Management  Overlapping Functions  Quality Improvement  
• Accreditation compliance  
• Claims management  
• Consumer / patient relations 
and disclosure  
• Contract / policy review  
• Corporate and regulatory 
compliance  
• Mandatory event reporting  
• Risk identification, e.g. near 
miss and adverse event 
reporting  
• Risk control, e.g. loss 
prevention and loss reduction  
• Risk financing  
• Safety and security  
• Workers compensation  
• Accreditation issues  
• Analysis of adverse and 
sentinel events and trends  
• Board reports  
• Consumer / patient complaint 
handling  
• Consumer / patient education  
• Feedback to staff and 
healthcare providers   
• Proactive risk assessments  
• Public reporting of quality 
data  
• Provider credentialing  
• Root-cause analysis  
• Staff education and training  
• Strategic planning  
  
• Accreditation coordination  
• Audits / benchmarking / 
clinical indicators etc.  
• Best practice / clinical 
guidelines  
• Consumer / patient  
satisfaction  
• Improvement projects  
• Peer review  
• Provider performance and 
competency  
• Quality methodology  
• Quality of care reviews  
• Utilization / resource /case 
management  
 
Users of the health care system also possess unique knowledge and experiences that can inform quality improvement efforts and help 
design systems around the needs of the patient rather than the staff or organization. However, there is much debate over how to 
meaningfully involve patients and caregivers in quality improvement. Experience suggests that projects have a clear rationale and 
defined roles and responsibilities for patients and caregivers [48].  
 
Exhibit 8. Roles that patients and caregivers have played in quality improvement [48] 
 Identifying improvement opportunities 
 Creating a sense of urgency for change with storytelling 
 Acting as an outlet to solicit other patient experiences  
 Offering change ideas to redesign systems of care 
 Persuading health care providers that quality of care problems exists and need to be addressed 
 
A staff lead is assigned as the primary liaison for the group, with 
one or more assistants who have the dual responsibility of 
supporting the lead and learning the process so they may serve 
as a future lead. Qualifications for staff lead include service as 
an assistant staff lead on a prior guideline panel, experience 
conducting literature searches and using a citation database, 
and a basic understanding of study design, medical 
terminology, and levels of evidence. Guidelines meeting certain 
quality standards are included in the NGC database, an initiative 
of the Agency for Healthcare Research and Quality NGC 
inclusion criteria are:  
1. The clinical practice guideline contains systematically 
developed statements that include recommendations, 
strategies, or information that assists physicians and/or 
other health care practitioners and patients make 
decisions about appropriate health care for specific clinical 
circumstances. 
2. The clinical practice guideline was produced under the 
auspices of medical specialty associations; relevant 
professional societies, public or private organizations, 
government agencies at the federal, state, or local level; or 
health care organizations or plans. A clinical practice 
guideline developed and issued by an individual not 
officially sponsored or supported by one of the above types 
of organizations does not meet the inclusion criteria for 
NGC. 
3. Corroborating documentation can be produced and 
verified that a systematic literature search and review of 
existing scientific evidence published in peer reviewed 
journals was performed during the guideline development. 
A guideline is not excluded from NGC if corroborating 
documentation can be produced and verified detailing 
specific gaps in scientific evidence for some of the 
guideline's recommendations. 
4. The full text guideline is available upon request in print or 
electronic format (for free or for a fee), in the English 
language. The guideline is current and the most recent 
version produced. Documented evidence can be produced 
or verified that the guideline was developed, reviewed, or 
revised within the last five years [51.52]. 
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9. Risk Management Processes and Strategies   
Risks should be considered using existing processes such as 
audits, data, trends, literature and risk assessment tools, as well 
as via planned reviews of issues with stakeholders through 
mechanisms such as brainstorming sessions. Tools used to 
screen and/or assess risks will vary depending on the risk being 
assessed. For example, consumer / patient risk screening 
and/or assessments such as falls risk or mobility assessment 
tools will be different from tools used to assess risks to 
achievement of strategic goals, or workplace safety risks. It is 
important that any tool used is validated by an expert internal 
source and/or agreed for use by the governing body. Examples 
of processes and strategies that assist with risk identification 
and management include:  
 
Exhibit 8. Five Basic Initiatives to Manage Risks [53] 
 Prevention: Proactive risk awareness and safety programs ensure that staff members are aware of 
potential risks and provide an understanding of how they can help protect patients, visitors and 
themselves. 
 Correction: Post-incident remedial actions minimize the impact of adverse events and help prevent 
future events.  
 Documentation:  Thorough and complete patient records, as well as comprehensive policies and 
procedures, facilitate better communication and stronger legal defense efforts when necessary.  
 Education: Creative and meaningful programs engage personnel in organizational risk-reduction 
initiatives, leading to a more empowered and effective staff.  
 Interdepartmental coordination: Creating a framework that encourages departments to work together 
fosters a safer organizational environment.  Together, these five elements allow 
 
Clinical examples   
 Collection and effective use of clinical indicators  
 Morbidity and mortality reviews  
 Clinical audits  
 Adverse outcome screening and clinical incident reporting   
 Health record audits and clinical content reviews  
 Medical emergency reviews   
 Medication management strategies  
 Consumer / patient risk assessments (e.g. Falls, pressure 
areas, VTE)  
 Peer review and peer supervision  
 Effective use of complaints and feedback from consumers 
/ patients and staff  
 Evidence, literature, research.   
  
Non-clinical examples  
 Collection and effective use of indicators relevant to the 
organization  
 Audit processes  
 Budget variance monitoring  
 Project activity reports   
 Purchasing and product evaluation   
 Fraud minimization schemes  
 WHS risk assessments and hazard identification  
 Lost time injury reports   
 Political change management strategies  
 Workplace safety strategies  
 Financial management strategies  
 Contingency and disaster planning  
 Redundancy in systems   
 Information technology and data entry system 
infrastructure and capabilities   
 Workforce planning   
 Credentialing and defining the scope of clinical practice 
for all clinicians  
 Recruitment and retention strategies  
 Education and mandatory training programs for staff  
 Staff performance review and development  
 Equipment maintenance and replacement schedules  
 External contract reviews [47].  
 
Conclusion 
Several activities proposed by the RMPs do not appear to be 
adequate in dealing with the potential risks of drugs. Poor 
communication of risk to practitioners and to the public, and 
above all limited transparency for the total assessment of risk, 
seem to transform RMPs into a tool to reassure the public when 
inadequately evaluated drugs are granted premature 
marketing authorization. As discussed previously, once the FDA 
guidance is finalized, certain new drug applications will require 
a Risk MAP. The purpose of this program will be to propose, 
design, implement and evaluate a number of interventions 
intended to minimize the risks of using the drug. In similar 
fashion to a clinical development program, the Risk MAP will 
have a defined set of goals and objectives, developed 
specifically for the drug in question. Each Risk MAP must specify 
the overall goals of the program, (eg, specifying that no 
pregnant woman be prescribed a specific drug). For each goal, 
one or more objectives should be specified. These are 
intermediate steps necessary for achieving the overall goal, for 
example, specifying that all physicians must fully inform women 
patients about the risks of taking a drug if pregnant. Finally, a 
number of tools or interventions must be specified that will aid 
in obtaining the specified goals and objectives, for example, 
specifying that there will be a brochure and a video drafted for 
physicians to distribute to patients. Each of these tools should 
be justified and pretested to help assure that they will achieve 
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their intended purpose(s). Risk management is a new and 
evolving discipline. It is difficult to argue that drugs should be 
provided to patients in a manner that minimizes potential 
hazards. The evaluation of safety of a pharmaceutical or 
biological product is carried out throughout the lifecycle of the 
compound. In order for a biopharmaceutical company to be 
prepared for post-approval safety monitoring, evaluation and 
mitigation, it must know what is required in terms of an RMP 
and a REMS and development of these tools must be started 
during drug development. Post-approval safety is not just a 
post-approval consideration.  The FDA has advanced the public 
health by fostering greater attention over the discovery, 
quantification, and management of risks. However, any policy 
that results in new activities to control one set of hazards may 
result in creating new, unexpected, hazards. Thus, continuing 
to evaluate the hazards of drugs and the interventions intended 
to control these hazards, is essential to assure that the benefits 
of a Risk Minimization Program will, itself, outweigh its risks. 
 
Abbreviations: Institute of Medicine (IOM); Risk Minimization 
Action Plan (Risk MAP); Committee for Medicinal Products for 
Human Use (CHMP); Benefit: Risk Assessment (BRA); European 
Medicines Agency (EMA); European Network of Centers for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP); 
Centers for Disease Control (CDC); Enterprise Risk Management 
(ERM); Hazardous Materials And Waste Disposals (HAZMAT); 
Post-Authorization Safety Studies (PASS); American Society for 
Health Care Risk Management (ASHRM); American Hospital 
Association (AHA); Healthcare Insurance Reciprocal of Canada 
(HIROC); National Health Service in England (NHS); Committee 
of sponsoring organizations of the treadway commission 
(COSO); Integrated Risk Management (IRM); The United States 
Agency for International Development (USAID); Institutional 
Review Boards (IRBs); Strengthening Collaboration for 
Operating Pharmacovigilance in Europe (SCOPE); Medicines 
and Healthcare products Regulatory Agency (MHRA); Drug 
Quality and Security Act/Drug Supply Chain Security Act 
(DQSA/DSCSA); Spontaneous Reporting Systems (SRSs); Active 
Surveillance (AS); Australian Register of Therapeutic Goods 
(ARTG); Periodic Safety Update Report (PSUR); National 
Competent Authority (NCA); Risk Minimization Measures 
(RMMs); Healthcare Associated Infections (HAI); European 
Union electronic Register of Post-Authorization Studies (EU PAS 
Register); National Safety and Quality Health Service (NSQHS); 
Work Health And Safety (WHS); Venous Thromboembolism 
(VTE); The Australian Council on Healthcare Standards (ACHS); 
National Guideline Clearinghouse (NGC)  
 
 
 
 
 
 
 
 
 
Article Highlights:  
 It is estimated that about 30%–40% of patients receive 
treatment that is not based on scientific evidence, and 
20%–25% receive treatments that are either not needed 
or potentially harmful.  
 More than 50% of Americans do not take medications as 
they are prescribed, and approximately one third do not 
finish the course of therapy or skip doses. 
 Risk perceptions (including deliberative, affective, and 
experiential) are often targeted in health behavior change 
interventions. 
 During the discovery phase, the analysis of the biological 
targets as well as medical chemistry will allow selection of 
lead molecules with the best BRA potential over hundreds 
of candidate molecules.  
 Unsafe health care provision is a main cause of increased 
mortality rate amongst hospitalized patients all over the 
world.  
 Risks should be considered using existing processes such 
as audits, data, trends, literature and risk assessment 
tools, as well as via planned reviews of issues with 
stakeholders through mechanisms such as brainstorming 
sessions. 
 Risk management and quality improvement systems are 
both directed to providing a structured framework for 
identification, analysis, treatment / corrective action, 
monitoring and review of risks, problems and/or 
opportunities.  
 Risk management plans also undergo quality assessments 
so the interventions and actions proposed are addressed 
as real potential issues. 
 Effort to enhance teaching of communication skills to 
medical trainees likely will require significant changes in 
instruction at undergraduate and graduate levels, as well 
as changes in assessing the developing communication 
skills of physicians.  
 84 % use of accurate brand names has been reported for 
insulins in the USA, whereas product-specific attribution 
of epoetins approached 99 % in the EU. 
 IRM Risk Register program in 2014. The 2016 top active 
risk themes were: patient care (30%); human resources 
(16%); financial (12%); leadership (11%); and information 
management/technology (10%).  
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